SCHEMBL1025950

SCHEMBL1025950

O=C(O)Nc1cccc(CCc2cccc(Nc3nc(Cl)ncc3Cl)c2)n1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 1/20 0.41
RHOA P61586 1/20 0.40
SYK P43405 1/20 0.39
CTSC P53634 3/20 0.39
BTK Q06187 3/20 0.38
EGFR P00533 4/20 0.38
CTSL P07711 1/20 0.38
CCNT1 O60563 1/20 0.38
CCNK O75909 1/20 0.38
CYP3A4 P08684 1/20 0.38
CCND3 P30281 1/20 0.38
CDK9 P50750 1/20 0.38
CDK6 Q00534 1/20 0.38
JAK3 P52333 2/20 0.37
BCL6 P41182 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1025753 0.90 SYK (0.46) KDM4EGAAALDH1A1RHOASYK
SCHEMBL1025168 0.88 NR3C2 (0.47) KDM4EGAAALDH1A1RHOACTSC
SCHEMBL13623053 0.86 STK17B (0.44) KDM4EGAAALDH1A1SYKCTSC
SCHEMBL4348221 0.85 ALDH1A1 (0.46) KDM4EGAAALDH1A1RHOASYK
SCHEMBL1024973 0.84 CTSC (0.40) RHOASYKCTSCBTKEGFR
SCHEMBL13623054 0.81 BCL6 (0.43) CTSCEGFRJAK3BCL6
SCHEMBL1027584 0.81 MAPT (0.51) GAAALDH1A1RHOABTKEGFR
Hydrochloric Acid SCHEMBL1026132 0.80 BCL6 (0.42) CTSCEGFRJAK3BCL6
SCHEMBL1025084 0.80 JAK3 (0.42) RHOACTSCBTKEGFRJAK3
SCHEMBL4333056 0.80 EGFR (0.41) RHOACTSCBTKEGFRJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK KDM4E 248/4885GAA 2377/4885ALDH1A1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.